Potential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract

키워드

참고문헌 (96)

1. Lanas A, "A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use", Am J Gastroenterol, 100, pp.1685~1693 (2005)
2. Lanas Á, "Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants", Clin Gastroenterol Hepatol, 13, pp.906~912 (2015)
3. Laine L, "Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac", Gastroenterology, 135, pp.1517~1525 (2008)
4. Lanas A, "Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice", Am J Gastroenterol, 104, pp.1633~1641 (2009)
5. Lanas A, "Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications", Gastroenterol Clin North Am, 38, pp.333~352 (2009)
6. Wallace JL, "NSAID gastropathy and enteropathy : distinct pathogenesis likely necessitates distinct prevention strategies", Br J Pharmacol, 165, pp.67~74 (2012)
7. Chan FK, "NSAID-associated lower gastrointestinal bleeding: where do we stand?", Clin Gastroenterol Hepatol, 10, pp.1060~1061 (2012)
8. Lanza FL, "Guidelines for prevention of NSAID-related ulcer complications", Am J Gastroenterol, 104, pp.728~738 (2009)
9. Goldstein JL, "Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy", Aliment Pharmacol Ther, 25, pp.1211~1222 (2007)
10. Hawkey CJ, "Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole", Clin Gastroenterol Hepatol, 6, pp.536~544 (2008)
11. Laine L, "Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use", Gastroenterology, 124, pp.288~292 (2003)
12. Chan FK, "Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis(CONDOR) : a randomised trial", Lancet, 376, pp.173~179 (2010)
13. Jarupongprapa S, "Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors : a systematic review and meta-analysis", J Gastroenterol, 48, pp.830~838 (2013)
14. Bjarnason I, "Misoprostol reduces indomethacin-induced changes in human small intestinal permeability", Dig Dis Sci, 34, pp.407~411 (1989)
15. Davies GR, "Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability", Dig Dis Sci, 38, pp.417~425 (1993)
16. Morris AJ, "Short report : the effect of misoprostol on the anaemia of NSAID enteropathy", Aliment Pharmacol Ther, 8, pp.343~346 (1994)
17. Raskin JB, "Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers : a comparison of three regimens", Ann Intern Med, 123, pp.344~350 (1995)
18. Rostom A, "Prevention of NSAID-induced gastroduodenal ulcers", Cochrane Database Syst Rev, (4), pp.CD002296~ (2002)
19. Watanabe T, "Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol : a pilot study", Clin Gastroenterol Hepatol, 6, pp.1279~1282 (2008)
20. Fujimori S, "Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin : a pilot randomized controlled trial evaluated by capsule endoscopy", Gastrointest Endosc, 69, pp.1339~1346 (2009)
21. Kyaw MH, "Misoprostol heals small bowel ulcers in aspirin users with small bowel bleeding", Gastroenterology, 155, pp.1090~1097 (2018)
22. Taha AS, "Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs(MASTERS) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Gastroenterol Hepatol, 3, pp.469~476 (2018)
23. Hawkey CJ, "Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator : proof of concept study in humans", Gut, 52, pp.1537~1542 (2003)
24. Fiorucci S, "Co-administration of nitric oxide-aspirin(NCX-4016)and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans", J Am Coll Cardiol, 44, pp.635~641 (2004)
25. Lohmander LS, "A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis", Ann Rheum Dis, 64, pp.449~456 (2005)
26. Bjarnason I, "Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy", Gut, 33, pp.1204~1208 (1992)
27. Montalto M, "Clinical trial : the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy : a randomized, double-blind, cross-over, placebo-controlled study", Aliment Pharmacol Ther, 32, pp.209~214 (2010)
28. Endo H, "Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users : a pilot randomized controlled study", J Gastroenterol, 46, pp.894~905 (2011)
29. Niwa Y, "Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects : a prospective, randomized, double-blinded, placebo-controlled, cross-over study", J Gastroenterol, 43, pp.270~276 (2008)
30. Thong-Ngam D, "Effect of rebamipide on gastric ulcer healing caused by Helicobacter pylori and", or NSAIDs or non NSAIDs-non H. pylori, 2009, pp.92, 1207~1212
31. Fujimori S, "Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury : a double-blind, randomized, controlled trial evaluated by capsule endoscopy", J Gastroenterol, 46, pp.57~64 (2011)
32. Mizukami K, "Aspirin-induced small bowel injuries and the preventive effect of rebamipide", World J Gastroenterol, 17, pp.5117~5122 (2011)
33. Mizukami K, "Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms", J Clin Biochem Nutr, 51, pp.216~220 (2012)
34. Zhang S, "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy : a systematic review and meta-analysis", Dig Dis Sci, 58, pp.1991~2000 (2013)
35. Kurokawa S, "A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and", or non-steroidal anti-inflammatory drug induced small bowel injury, 2014, pp.49, 239~244
36. Watanabe T, "A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage", PLoS One, 10, pp.e0122330~ (2015)
37. Ota K, "Determination of the adequate dosage of rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-induced gastrointestinal mucosal injury", J Clin Biochem Nutr, 59, pp.231~237 (2016)
38. Kuramoto T, "Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study", BMC Gastroenterol, 13, pp.85~ (2013)
39. Isomura Y, "Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs", Gastrointest Endosc, 80, pp.118~125 (2014)
40. Kojima Y, "Effect of long-term proton pump inhibitor therapy and healing effect of irsogladine on nonsteroidal anti-inflammatory drug-induced small-intestinal lesions in healthy volunteers", J Clin Biochem Nutr, 57, pp.60~65 (2015)
41. 심기남, "The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis", The Korean Journal of Internal Medicine, 34(5), pp.1008~1021 (2019), 대한내과학회[DOI]
42. Hayllar J, "Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss : effects of sulfasalazine and other disease-modifying antirheumatic drugs", Arthritis Rheum, 37, pp.1146~1150 (1994)
43. Ota K, "Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal mucosal injury : a randomized, double-blind, pilot study", BMC Gastroenterol, 19, pp.4~ (2019)
44. Iguchi M, "Effect of egualen sodium hydrate on small-intestinal mucosal damage induced by low-dose aspirin : a prospective randomized clinical trial", J Clin Biochem Nutr, 62, pp.174~178 (2018)
45. Huang C, "Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury", World J Gastroenterol, 20, pp.11012~11018 (2014)
46. Latimer N, "Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis", BMJ, 339, pp.b2538~ (2009)
47. Schnitzer TJ, "Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial(TARGET), reduction in ulcer complications : randomised controlled trial", Lancet, 364, pp.665~674 (2004)
48. Dajani EZ, "Selective COX-2 inhibitors and gastrointestinal mucosal injury : pharmacological and therapeutic considerations", J Assoc Acad Minor Phys, 11, pp.28~31 (2000)
49. Hunt RH, "Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib", Aliment Pharmacol Ther, 17, pp.201~210 (2003)
50. Wallace JL, "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself?", Physiol Rev, 88, pp.1547~1565 (2008)
51. Whittle BJ, "Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat", Gastroenterology, 80, pp.94~98 (1981)
52. Bjarnason I, "Experimental evidence of the benefit of misoprostol beyond the stomach in humans", J Rheumatol Suppl, 20, pp.38~41 (1990)
53. Davies NM, "Detection and prevention of NSAID-induced enteropathy", J Pharm Pharm Sci, 3, pp.137~155 (2000)
54. MacNaughton WK, "Endothelium-derived relaxing factor(nitric oxide)has protective actions in the stomach", Life Sci, 45, pp.1869~1876 (1989)
55. Wallace JL, "Nitric oxide in mucosal defense : a little goes a long way", Gastroenterology, 119, pp.512~520 (2000)
56. Wallace JL, "The therapeutic potential of NO-NSAIDs", Fundam Clin Pharmacol, 17, pp.11~20 (2003)
57. Lanas A, "Role of nitric oxide in the gastrointestinal tract", Arthritis Res Ther, 10, pp.S4~ (2008)
58. Wallace JL, "Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat", Gastroenterology, 107, pp.173~179 (1994)
59. Wallace JL, "Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats", Gastroenterology, 117, pp.557~566 (1999)
60. Tashima K, "Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats", Life Sci, 67, pp.1639~1652 (2000)
61. Wallace JL, "A diclofenac derivative without ulcerogenic properties", Eur J Pharmacol, 257, pp.249~255 (1994)
62. Davies NM, "NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects", Aliment Pharmacol Ther, 11, pp.69~79 (1997)
63. Reuter BK, "Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2", J Clin Invest, 98, pp.2076~2085 (1996)
64. Bonner GF, "Exacerbation of inflammatory bowel disease associated with use of celecoxib", Am J Gastroenterol, 96, pp.1306~1308 (2001)
65. Reuter BK, "Markedly reduced intestinal toxicity of a diclofenac derivative", Life Sci, 55, pp.PL1~PL8 (1994)
66. Lanas A, "Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?", Digestion, 73, pp.136~150 (2006)
67. Otani K, "Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage", Digestion, 95, pp.22~28 (2017)
68. Uejima M, "Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug", Microbiol Immunol, 40, pp.553~560 (1996)
69. Robert A, "Resistance of germfree rats to indomethacin-induced intestinal lesions", Prostaglandins, 14, pp.333~341 (1977)
70. Wallace JL, "Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis", Gastroenterology, 141, pp.1314~1322 (2011)
71. Scarpignato C, "NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?", Gut, 57, pp.145~148 (2008)
72. Fornai M, "Small bowel protection against NSAID-injury in rats : effect of rifaximin, a poorly absorbed, GI targeted, antibiotic", Pharmacol Res, 104, pp.186~196 (2016)
73. Colucci R, "Pathophysiology of NSAID-associated intestinal lesions in the rat : luminal bacteria and mucosal inflammation as targets for prevention", Front Pharmacol, 9, pp.1340~ (2018)
74. Kinouchi T, "Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation", Microbiol Immunol, 42, pp.347~355 (1998)
75. Koga H, "Experimental enteropathy in athymic and euthymic rats : synergistic role of lipopolysaccharide and indomethacin", Am J Physiol, 276, pp.G576~G582 (1999)
76. Banerjee AK, "Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat : similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors", Gut, 31, pp.1358~1364 (1990)
77. Lombardo L, "Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy", Clin Gastroenterol Hepatol, 8, pp.504~508 (2010)
78. Shen J, "Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis : meta-analysis of randomized controlled trials", Inflamm Bowel Dis, 20, pp.21~35 (2014)
79. Zhang Y, "Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria : a meta-analysis", BMC Gastroenterol, 16, pp.62~ (2016)
80. Hempel S, "Probiotics for the prevention and treatment of antibiotic-associated diarrhea : a systematic review and meta-analysis", JAMA, 307, pp.1959~1969 (2012)
81. Szajewska H, "Meta-analysis : Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials", Aliment Pharmacol Ther, 38, pp.467~476 (2013)
82. Gallo A, "Modulation of microbiota as treatment for intestinal inflammatory disorders : an uptodate", World J Gastroenterol, 22, pp.7186~7202 (2016)
83. Rostom A, "Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks", Aliment Pharmacol Ther, 29, pp.481~496 (2009)
84. Yeomans ND, "A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial : Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment(ASTRONAUT)Study Group", N Engl J Med, 338, pp.719~726 (1998)
85. Satoh H, "Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats", J Pharmacol Exp Ther, 348, pp.227~235 (2014)
86. Gwee KA, "Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs : risks versus benefits", J Pain Res, 11, pp.361~374 (2018)
87. Williams C, "Review article : proton pump inhibitors and bacterial overgrowth", Aliment Pharmacol Ther, 23, pp.3~10 (2006)
88. Nagata N, "Acute middle gastrointestinal bleeding risk associated with NSAIDs, antithrombotic drugs, and PPIs : a multicenter case-control study", PLoS One, 11, pp.e0151332~ (2016)
89. Kamada T, "Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication : a multicenter study", Biomed Res Int, 2015, pp.865146~ (2015)
90. Arakawa T, "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine", Dig Dis Sci, 40, pp.2469~2472 (1995)
91. Tanigawa T, "Rebamipide inhibits indomethacin-induced small intestinal injury : possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5", Eur J Pharmacol, 704, pp.64~69 (2013)
92. Imaeda H, "Terminal-restriction fragment length polymorphism(T-RFLP)analysis for changes in the gut microbiota profiles of indomethacin-and rebamipide-treated mice", Digestion, 86, pp.250~257 (2012)
93. Hiraishi H, "Clinical trial : irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection : the results of a multicentre, double-blind, randomized clinical trial(IMPACT study)", Aliment Pharmacol Ther, 31, pp.824~833 (2010)
94. Kamei K, "Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats", Dig Dis Sci, 53, pp.2657~2666 (2008)
95. Menozzi A, "Effects of oral curcumin on indomethacin-induced small intestinal damage in the rat", Drug Discov Ther, 3, pp.71~76 (2009)
96. Sivalingam N, "Curcumin reduces indomethacin-induced damage in the rat small intestine", J Appl Toxicol, 27, pp.551~560 (2007)

관련 논문AI추천